AIP
CLSD

Ameritas Investment Partners’s Clearside Biomedical CLSD Stock Holding History

Ameritas Investment Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-121
Closed -$3K – 3055
2019
Q1 		$3K Hold
121
– – ﹤0.01% 2910
2018
Q4 		$2K Hold
121
– – ﹤0.01% 2946
2018
Q3 		$11K Hold
121
– – ﹤0.01% 2792
2018
Q2 		$19K Hold
121
– – ﹤0.01% 2534
2018
Q1 		$19K Hold
121
– – ﹤0.01% 2443
2017
Q4 		$13K Hold
121
– – ﹤0.01% 2650
2017
Q3 		$12K Hold
121
– – ﹤0.01% 2690
2017
Q2 		$17K Buy
121
+82
+210% +$9.85K ﹤0.01% 2550
2017
Q1 		$5K Buy
+39
New +$4.6K ﹤0.01% 2832

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Ameritas Investment Partners's CLSD Position: Q2 2019 in Review

Ameritas Investment Partners sold out of Clearside Biomedical (CLSD) in Q2 2019, closing a stake of 121 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in CLSD in Q1 2017 and held it in 9 quarters. The position peaked at $19K in Q2 2018. 50 funds tracked by Wall St. Rank hold CLSD as of Q2 2019.

  • Ameritas Investment Partners reported no remaining Clearside Biomedical position as of Q2 2019 after selling out during the quarter.
  • Ameritas Investment Partners sold 121 Clearside Biomedical shares in Q2 2019, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Clearside Biomedical in Q1 2017 and held it in 9 quarters.
  • Ameritas Investment Partners's Clearside Biomedical position peaked at $19K in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2019.

Based on Ameritas Investment Partners's 13F filing for Q2 2019, filed 14 Aug 2019.